, I have received consultancy fees and non-personal research grants from Merck, Novartis, Biogen, and Sanofi, and grants from Teva, outside the area of work being

R. Kapoor, P. Ho, and N. Campbell, Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension, Lancet Neurol, issue.18, pp.30069-30072, 2018.

J. A. Cohen, G. R. Cutter, and J. S. Fischer, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, pp.679-87, 2002.

H. Tremlett, Y. Zhao, J. Joseph, V. Devonshire, and . Neurologists,

, J Neurol Neurosurg Psychiatry, vol.79, pp.1368-74, 2008.

, European Study Group on interferon beta-1b in SPMS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, vol.352, pp.1491-97, 1998.

H. Panitch, A. Miller, and D. Paty, Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study, Neurology, vol.63, pp.1788-95, 2004.

K. Hawker, P. O'-connor, and M. S. Freedman, Rituximab in patients with primary progressive MS. Results of a randomized double blind placebo controlled trial, Ann Neurol, vol.66, pp.960-71, 2009.

X. Montalban, S. L. Hauser, and L. Kappos, Ocrelizumab versus placebo in primary progressive multiple sclerosis, N Engl J Med, vol.376, pp.209-229, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01793440

F. Lublin, S. T. Reingold, and J. A. Cohen, Defining the clinical course of multiple sclerosis. The 2013 revisions, Neurology, vol.83, pp.278-86, 2014.